EP
TXG icon

Essential Partners’s 10x Genomics TXG Stock Holding History

Essential Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$315K Sell
3,489
-1,119
-24% -$65.5K 0.14% 151
2026
Q2 		$177K Sell
4,608
-620
-12% -$16.2K 0.08% 268
2026
Q1 		$111K Hold
5,228
– – 0.04% 401
2025
Q4 		$85.3K Sell
5,228
-13
-0.2% -$196 0.03% 485
2025
Q3 		$61.3K Buy
5,241
+36
+0.7% +$469 0.02% 551
2025
Q2 		$60.3K Buy
+5,205
New +$47.4K 0.02% 431

Other funds holding TXG

Counterpoint Mutual Funds
Counterpoint Mutual Funds San Diego, California $1.16B AUM 33.78% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Aaron Wealth Advisors
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Krilogy Financial
Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return
Frank Rimerman Advisors
Frank Rimerman Advisors Palo Alto, California $1.81B AUM 32.96% 1-Year Est. Return

Essential Partners's TXG Position: Q3 2026 in Review

Essential Partners reduced its 10x Genomics (TXG) stake by 24% in Q3 2026, selling an estimated $65.5K and leaving 3,489 shares worth $315K. The position accounts for 0.14% of the portfolio, ranked #151.

Essential Partners first reported a position in TXG in Q2 2025 and has held it in 6 quarters since. 42 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Essential Partners held 3,489 shares of 10x Genomics worth $315K as of Q3 2026.
  • Essential Partners sold 1,119 10x Genomics shares in Q3 2026, an estimated $65.5K.
  • 10x Genomics made up 0.14% of Essential Partners's portfolio in Q3 2026, its #151 holding.
  • Essential Partners first reported a position in 10x Genomics in Q2 2025 and has held it in 6 quarters since.
  • 42 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.